Scalable Success
Numbers may hold the clue for a successful weight loss program at your company.
Discover how big numbers and a broad population helped to drive clinically significant results for employee weight loss programs using an intent-to-treat analysis.
Real Appeal delivers more than 2:1 ROI in 3 Years
In a first-of-its-kind, peer-reviewed study analyzing real-world claims data of nearly 15,000 participants, Real Appeal demonstrated more than 2:1 ROI in Three Years.
Read More
Study: Help reduce cholesterol and lower the risk of heart disease with Real Appeal
Being overweight or obese may increase your cholesterol and the associated risk for heart disease. Real Appeal found its members better reduced their cholesterol levels in comparison to non-participants.
Read More
White Paper: Every Pound Lost Can Make a Difference for Your Health
Most people assume they have to lose a significant amount of weight to see health benefits; however, research shows losing as little as 3% or 5% body weight can improve a person’s health. Real Appeal’s data reveals the more program sessions a member attended, the more likely he or she was to achieve 5% weight loss — which can help lower blood pressure, reduce the risk of developing type 2 diabetes and reduce health care costs.
Read More
White Paper: Making the Science of Behavior Change Appealing
The healthcare industry is facing significant cost increases driven by obesity-related chronic conditions. Traditional weight loss and disease prevention programs have limited success because they don’t address the major obstacles to long term behavior change. Real Appeal’s research reveals strategies and tools that are effective in driving engagement and program persistence.
Read More
ROI Study: Real Appeal Is on Track to Meet or Exceed 2:1 ROI over Three Years
Real Appeal’s unique ability to drive participation and produce clinically significant weight loss can translate into meaningful cost savings. An analysis of claims from nearly 22,000 participants demonstrated a 1.5:1 ROI in just 24 months.
Read More
Study: Real medical cost reduction
A recent large-scale claims analysis found that Real Appeal delivered a 1:1 ROI in year one, shaving medical costs by as much as 16 percent.
Read More
Want to dig in to what really makes us different? We’ve pulled together peer-reviewed research articles from academic publications that show why we’re able to guarantee our results.
Consensus on Safe and Effective Lifestyle Strategies for Weight Loss
Learn MoreIntensive Lifestyle Interventions for Overweight and Obesity Scientific Basis and History
Learn MoreIs 5 Percent Weight Loss Satisfactory Criterion for Clinically Significant Weight Loss
Learn MoreLong Term Weight Loss with Behavior Change is Possible
Learn MoreModest Weight Loss Can Prevent Type 2 Diabetes
Learn MoreCaloric Restriction is Safe and Effective for Weight Loss and Health Benefits
Learn MoreYou Can Lose Weight Using a Variety of Diet Plans
Learn MoreU.S. Preventive Services Task Force Guidelines on Preventive Care
Learn MoreFifty Years of Behavioral/Lifestyle Interventions for Overweight and Obesity: Where Have We Been and Where Are We Going?
Learn MoreLed by experts with real passion.
Our Clinical Advisory Board carefully oversees and guides the addition of each new tool and idea, ensuring consistent support and healthier transformations for each member.
-
Caroline Apovian, M.D., FACP, FACN
-
Louis J. Aronne, M.D., FACP
-
John Foreyt, Ph.D.
-
Jaime Murillo, M.D., FACC, FASE
-
Donna Ryan, M.D.
-
Steven R. Smith, M.D.
-
Donald A. Williamson, Ph.D.
Close Modal
![Caroline Apovian, M.D., FACP, FACN](https://realappeal-cdn.prod.werally.in/Caroline-Apovian.jpg)
- Professor of Medicine & Pediatrics; Endocrinology, Diabetes, Nutrition; Boston University School of Medicine
- Director, Nutrition and Weight Management Center; Boston Medical Center
- Director, Nutrition and Support Service; Boston Medical Center
Caroline Apovian
M.D., FACP, FACN
For over twenty-five years, Dr. Apovian has held a position at the forefront of the weight-management and nutrition field. One of the world’s premier weight-loss experts, she has distinguished herself as a leading researcher, treatment provider, teacher, and New York Times bestselling author. She is a nutrition consultant to NASA, and an appointed member of the federal government’s panel on the evaluation and treatment of overweight adults.
Close Modal
![Louis J. Aronne, M.D., FACP](https://realappeal-cdn.prod.werally.in/Lou_Aronne.jpg)
- Past president of The Obesity Society
- Awards for teaching include the Leo M. Davidoff Society Prize from Albert Einstein College of Medicine and Eliot Hochstein Teaching Award from Cornell University
- Regularly ranked as a Best Doctor in New York as a specialist in obesity and internal medicine
Louis J. Aronne
M.D., FACP
A renowned expert in the field of weight research, Dr. Aronne has written a New York Times best-seller and is often quoted by the media. A founding board member of the American Board of Obesity Medicine, he is the Weill Professor of Metabolic Research and Professor of Clinical Medicine at Weill Cornell Medical College, an attending physician at New York Presbyterian Hospital, and an Adjunct Clinical Associate Professor of Medicine at Columbia University.
Close Modal
![John Foreyt, Ph.D.](https://realappeal-cdn.prod.werally.in/John_Foreyt.jpg)
- Former member of the National Task Force on the Prevention and Treatment of Obesity, National Institutes of Health
- Served on the Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults
- Fellow of the Society of Behavioral Medicine, the Obesity Society, the Academy of Behavioral Medicine Research and other professional associations
John Foreyt
Ph.D.
Dr. Foreyt is Professor at the Baylor College of Medicine’s Department of Medicine and Department of Psychiatry, and is the Director of the DeBakey Health Center’s Behavioral Medicine Research Center. He has published 17 books and more than 400 articles in the areas of diet modification, cardiovascular risk reduction, eating disorders, and obesity, and is on the editorial boards of Eating Disorders; Obesity Research and Clinical Practice; Childhood Obesity; and Nutrition Today.
Close Modal
![Jaime Murillo, M.D., FACC, FASE](https://realappeal-cdn.prod.werally.in/Jamie_Murillo.jpg)
- Senior VP and Chief Medical Officer at OptumLabs, UnitedHealth Group
- Cardiologist from Yale University and Harvard Medical School fellow
- Nearly 20 years of experience in general cardiology with subspecialty in imaging at Sentara Healthcare System
Jaime Murillo
M.D., FACC, FASE
With decades of experience in clinical practice and an extensive background in computer sciences, AI, and research, Dr. Murillo is Senior VP and Chief Medical Officer at OptumLabs, UnitedHealth Group, with a focus on early detection of cardiometabolic disease, prevention at a population level, predictive analytics, as well as health equity in research. He also spent 3 years collaborating with IBM Watson on machine learning technology development. Prior to his current role at OptumLabs, he spent 2 years at UnitedHealthcare as the national lead for cardiovascular services focused on simple innovation and value-based transformation of cardiovascular care and affordability.
Close Modal
![Donna Ryan, M.D.](https://realappeal-cdn.prod.werally.in/Donna_Ryan.jpg)
- Professor Emeritus, Pennington Biomedical Research Center
- Investigator, Diabetes Prevention Program (DPP)
Donna Ryan
M.D.
Dr. Ryan has contributed significantly to obesity education and, in particular, training primary care physicians to incorporate obesity management into their medical practices. She is an editorial board member for Obesity Management and Obesity Reviews, and her scholarly activities include authorship of 104 original publications and 27 chapters and review. Since 1998, she has served as Co-Principal Investigator for the Centers of Obesity Research and Education.
Close Modal
![Steven R. Smith, M.D.](https://realappeal-cdn.prod.werally.in/Steven_Smith.jpg)
- Professor, Metabolic Disease Program, Sanford-Burnham Medical Research Institute
- Scientific Director, Translational Research Institute for Metabolism and Diabetes
- Chief Scientific Officer, Florida Hospital
Steven R. Smith
M.D.
Dr. Smith’s research focuses on adipose tissue biology and skeletal muscle energetics/fatty acid oxidation. His clinical research program focuses on substrate switching, pharmacotherapy of obesity and diabetes, and personalized therapy based on clinical subtypes. He is active in clinical trials of drugs for obesity and diabetes, published over 100 original articles, reviews, and book chapters and serves on the editorial boards of Obesity, the International Journal of Obesity, and Diabetes.
Close Modal
![Donald A. Williamson, Ph.D.](https://realappeal-cdn.prod.werally.in/Don_Williamson.jpg)
- Dr. Williamson was named John S. McIlhenny Endowed Professor of Nutrition in 2003. He has authored more than 350 research papers and book chapters as well as The Intimacy Paradox: Personal Authority in the Family System.
- Served as primary investigator for three NIH-sponsored studies related to the prevention of weight gain in children and adolescents (HIPTeens, Wise Mind, and LA Health), as co-PI for the NIH-sponsored CALERIE study, and was a key investigator for the NIH-sponsored Pounds Lost study.
Donald A. Williamson
Ph.D.
Dr. Williamson has conducted research and clinical practice in the field of obesity for 39 years, and has held the rank of Professor Emeritus at Pennington Biomedical Center since 2011. His deep involvement in obesity research includes serving as co-investigator of the Diabetes Prevention Program and the Look AHEAD studies, and as primary investigator for three Department of Defense studies testing the efficacy of an internet-based weight management and physical fitness program.
*In the past 20 years, researchers have demonstrated that structured weight-loss and lifestyle-change programs can accomplish three critical employee and population health goals:1. Improving overall health outcomes for individuals who are overweight and obese but do not yet have prediabetes or diabetes (Jensen, M.D., Ryan, D.H., Donato, K.A. et al, 2014) 2. Reducing the progression to diabetes in those who have prediabetes (Williamson, D.A., Bray, G.A., & Ryan, D.H, 2015) 3. Improving clinical markers for individuals who already have Type 2 diabetes (Espeland, M.A., Glick, H.A., Bertoni, A., et al for the Look AHEAD Research Group, 2014)